Tissue-engineered trachea from sheep marrow stromal cells with transforming growth factor beta2 released from biodegradable microspheres in a nude rat recipient

J Thorac Cardiovasc Surg. 2004 Jul;128(1):147-53. doi: 10.1016/j.jtcvs.2004.02.038.

Abstract

Objective: The purpose of this study was to evaluate the feasibility of using autologous sheep marrow stromal cells cultured onto polyglycolic acid mesh to develop helical engineered cartilage equivalents for a functional tracheal replacement. We also explored the potential benefit of local delivery of transforming growth factor beta 2 with biodegradable gelatin microspheres.

Methods: Bone marrow was obtained by iliac crest aspiration from 6-month-old sheep and cultured in monolayer for 2 weeks. At confluence, the cells were seeded onto nonwoven polyglycolic acid fiber mesh and cultured in vitro with transforming growth factor beta 2 and insulin-like growth factor 1 for 1 week. Cell-polymer constructs were wrapped around a silicone helical template. Constructs were then coated with microspheres incorporating 0.5 microg transforming growth factor beta 2. The cell-polymer-microsphere structures were then implanted into a nude rat. On removal, glycosaminoglycan content and hydroxyproline were analyzed in both native and tissue-engineered trachea. Histologic sections of both native and tissue-engineered trachea were stained with hematoxylin and eosin, safranin-O, and a monoclonal anti-type II collagen antibody.

Results: Cell-polymer constructs with transforming growth factor beta 2 microspheres formed stiff cartilage de novo in the shape of a helix after 6 weeks. Control constructs lacking transforming growth factor beta 2 microspheres appeared to be much stiffer than typical cartilage, with an apparently mineralized matrix. Tissue-engineered trachea was similar to normal trachea. Histologic data showed the presence of mature cartilage. Glycosaminoglycan and hydroxyproline contents were also similar to native cartilage levels.

Conclusions: This study demonstrates the feasibility of engineering tracheas with sheep marrow stromal cells as a cell source. Engineering the tracheal equivalents with supplemental transforming growth factor beta 2 seemed to have a positive effect on retaining a cartilaginous phenotype in the newly forming tissue.

Publication types

  • Comparative Study
  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Absorbable Implants*
  • Animals
  • Biomarkers / analysis
  • Bone Marrow Cells / metabolism*
  • Bone Marrow Cells / pathology
  • Cartilage / metabolism
  • Cartilage / pathology
  • Collagen Type II / metabolism
  • Coloring Agents
  • Eosine Yellowish-(YS)
  • Equipment Design
  • Feasibility Studies
  • Gelatin / pharmacology
  • Hematoxylin
  • Microspheres*
  • Models, Cardiovascular
  • Polyglycolic Acid / pharmacology
  • Rats
  • Rats, Nude
  • Sheep
  • Stromal Cells / metabolism*
  • Stromal Cells / pathology
  • Tissue Engineering*
  • Trachea / cytology*
  • Trachea / drug effects
  • Trachea / surgery*
  • Transforming Growth Factor beta / drug effects
  • Transforming Growth Factor beta / metabolism*

Substances

  • Biomarkers
  • Collagen Type II
  • Coloring Agents
  • Transforming Growth Factor beta
  • Polyglycolic Acid
  • Gelatin
  • Eosine Yellowish-(YS)
  • Hematoxylin